"AST\/ALT ratio"

AST/ALT ratio as a potential predictor of 1-year mortality in elderly patients operated for femoral neck fracture. Hip fractures in elderly individuals are associated with high mortality rates, even with advanced treatment options. Identifying factors correlated with mortality could guide potential preventive strategies. Elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT ) levels, as well as the AST/ALT ratio (AAR), have been associated with mortality in various diseases, but their association with hip fracture mortality remains underexplored. This study investigates the correlation between AST, ALT, AAR, and routine laboratory parameters with 1-year mortality in elderly patients undergoing partial hip arthroplasty for femoral neck fractures. This retrospective cohort

The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. To evaluate the prognostic value of the pre-treatment aspartate transaminase (AST)/alanine transaminase (ALT) ratio in hepatocellular carcinoma (HCC) patients receiving radiofrequency ablation (RFA)/microwave ablation (MWA) combined with simultaneous TACE . The data for 117 patients were retrospectively analyzed in this study. The endpoint of prognosis was overall survival (OS). The Youden index was used to choose the optimal cut-off value of the pre-treatment AST/ALT ratio for OS prediction. Univariate and multivariate analyses were used to identify independent risk factors, then integrated to establish the nomogram. The AST/ALT ratio cut-off value for OS

AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. Chronic hepatitis B (CHB) is a significant risk factor for liver-related disorders. Hepatic fibrosis staging by liver biopsy in these patients can lead to complications. This study aimed to compare aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, AST to platelet ratio index (APRI), and fibrosis-4 (FIB-4) with FibroScan results for the evaluation of hepatic fibrosis in CHB patients. This cross-sectional study included patients with CHB referred to the outpatient clinics of Bandar Abbas, Hormozgan, Iran, in 2021. The age and sex of the participants were noted. FibroScan evaluation was done for all subjects. Moreover, AST

Association between Plasmatic Ceramides Profile and AST/ALT Ratio: C14:0 Ceramide as Predictor of Hepatic Steatosis in Adolescents Independently of Obesity To assess the association between plasma ceramides and hepatic steatosis (HS) in adolescents, independently of obesity. Ninety-four adolescents from two previous studies conducted and published by our crew were included. Study subjects were

Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a cause of chronic liver disease. It has also been associated with devastating outcomes such as decompensated liver cirrhosis and hepatocellular carcinoma, as well as diabetes and metabolic syndrome. This study was conducted in order to assess liver fibrosis using Fibroscan, and to compare these results to the use of Fibrosis-4 (FIB-4) scores, AST platelet ratio index (APRI scores), and the AST/ALT ratios on NAFLD patients. A cross sectional study was conducted on NAFLD patients who underwent Fibroscan examinations between September 1, 2011 and June 30, 2014. Demographic data

to estimate the three-year risk of HCC development. Both models are accessible at www.hccrisk.com. The HCC Risk model includes variables such as age, gender, diabetes, body mass index, platelet count, serum albumin and AST/√ALT ratio, and was derived based on retrospective data from 23,243 patients. After a three-year follow-up, acceptable discrimination was reported with AUCs of 0.76 and 0.75

. Patients with normal ALT and AST levels can be considered for evaluation for hepatic steatosis when multiple risk factors are present, particularly type 2 diabetes. The NAFLD fibrosis score is a tool for predicting the presence of fibrosis that is calculated with an online formula using readily available clinical data consisting of age, BMI, hyperglycemia, platelet count, albumin, and AST/ALT ratio.80

-linear relationship between liver enzymes and cognitive performance. In this cross-sectional study, 2764 individuals aged ≥ 60 who participated in the National Health and Nutrition Survey (NHANES) between 2011 and 2014 were included. The primary data comprised liver enzyme levels (alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), AST/ALT ratio, and gamma : 1.11-1.98), whereas ALT demonstrated a positive association with the consortium to establish a registry for Alzheimer's disease (CERAD) test score (OR = 0.72, 95% CI: 0.53-0.97). Additionally, the AST/ALT ratio was negatively associated with the global cognitive test (OR = 2.39, 95% CI: 1.53-3.73), CERAD (OR = 2.61, 95% CI: 1.77-3.84), and digit symbol substitution test (DSST) scores (OR = 2.51, 95

patients, the aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio showed the highest AUC (0.676, 95% CI, 0.575-0.776) among laboratory parameters with different distributions between the groups. AST/ALT was also identified as an independent predictor of poor treatment outcome (OR = 3.672, 95% CI, 1.455-9.268, p = 0.006). Adding AST/ALT to CURB-65 slightly increased the AUC, but remarkably enhanced NRI and IDI (AUC, 0.756 vs. 0.782, p = 0.017; continuous NRI, 0.635, 95% CI, 0.304-0.966, p < 0.001; categorical NRI, 0.175, 95% CI, 0.044-0.307, p = 0.009; IDI, 0.043, 95% CI, 0.006-0.080, p = 0.021). An AST/ALT ratio of ≥ 1.625 conferred a 74% post-test probability of poor treatment outcome, while < 1.625 predicted 21%. AST/ALT also predicted outcomes for all the CAP patients enrolled

to determine fatty liver. We studied 146 obese children with a mean age (SD) 9.86 (2.1) years. The fatty liver group showed significantly elevated levels (p < 0.05) of UA, oral glucose tolerance test (OGTT), triglycerides (TG), AST, ALT, GGT, insulin resistance (HOMA-IR) and a reduced AST/ALT ratio, compared to the non-fatty liver group. Chi square test showed statistically significant associations between fatty liver and AST, ALT, AST/ALT ratio, HOMA-IR, UA and GGT. With existing cut offs, GGT (> 30 U/L) and UA (> 330 µmol/L) the sensitivity and specificity of GGT in predicting fatty liver was 26.9% and 94.1% respectively while for UA it was 38.5% and 83.8% respectively. A cut-off value of 18.5 U/L (sensitivity 76.9% and specificity 52.9%) for GGT, 277µmol/L (sensitivity 70.5% and specificity 57.4

, 43 (16.29%) achieved complete resolution while 221 (83.71%) showed persistent calculi. Univariate analysis revealed significant differences between groups in gender (χ = 4.738, P = 0.030), concurrent cholecystitis (χ = 24.424, P < 0.001), cholangitis (P = 0.001), viral hepatitis (χ = 3.957, P = 0.047), decompensated cirrhosis (χ = 6.827, P = 0.009), Age Groups (t=-2.232, P = 0.030), AST/ALT ratio [OR = 0.237, 95% CI (0.106-0.529), P < 0.001], cholangitis [OR = 0.258, 95% CI (0.075-0.889), P = 0.032], and elevated white blood cell count [OR = 0.876, 95% CI (0.806-0.953), P = 0.002] are negatively associated with the resolution of pseudolithiasis. In contrast, the increase in the AST/ALT ratio [OR = 5.132, 95% CI(2.063-12.766), P < 0.001] and the use of iodinated contrast agents [OR = 3.944, 95% CI

logistic regression analysis identified 9 novel potential biomarkers including 5 blood-based biomarkers (plateletocrit, calcium, insulin, AST/ALT ratio, total bilirubin), urine pH, and body fat measurements in the arm, leg, and thigh. This study illustrated the characteristics and potential alternative and novel biomarkers of MAFLD based on a Chinese paediatric cohort. These findings posed new paths

counts were not associated with OS (p > 0.05 for all). However, a higher FIB-4 index (p = 0.025), ALBI score (p < 0.001), GPR (p < 0.001), and AST/ALT ratio (p < 0.001) were all associated with poor OS. Additionally, multivariate Cox regression analysis indicated that age (95% CI: 1.009-1.053, p = 0.006), ALBI score (95% CI: 1.234-2.983, p = 0.004), GPR (95% CI: 1.442-2.701, p < 0.001), and AST/ALT (95

Non-linear association between aspartate aminotransferase to alanine aminotransferase ratio and mortality in critically ill older patients: A retrospective cohort study. The aspartate aminotransferase to alanine aminotransferase (AST/ALT) ratio has been shown to be associated with poor clinical outcomes across various patient groups. However, little is unclear about the association between the two in critically ill older patients. Therefore, we aim to investigate the association of the AST/ALT ratio with hospital mortality in this special population. In this retrospective cohort study, we extracted elderly patients (age ≥ 65 years) from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The primary outcome was in-hospital mortality. The association between the AST/ALT

) considering the younger group (17-44 years old) as the reference, presence of hypoxemia (HR = 1.40, 95% CI: 1.01-1.95), hypoglycemia and hospital hyperglycemia (HR = 1.99, 95% CI: 1.01-3.91, and HR = 1.27, 95% CI: 0.99-1.62, respectively) when compared with normoglycemia, an AST-ALT ratio >1 (HR = 1.55, 95% CI: 1.25-1.92), C-reactive protein level (CRP) of >10 mg/dL (HR = 1.49, 95% CI: 1.07-2.08), arterial of 70.28%, and a correct classification rate of 72.66%. The LR+ (3.1328) and LR- (0.0981) values further support its efficacy in identifying high-risk patients. Male sex, increasing age, hypoxemia, hypoglycemia or hospital hyperglycemia, AST-ALT ratio >1, elevated CRP, altered arterial pH, and leucocytosis were factors significantly associated with higher mortality in hospitalized patients with COVID-19

with STZ developed polydipsia, became hypertensive and hyperglycemic. HFD induced weight gain, protected against glomerular hypertrophy, scarring, and albuminuria at endpoint compared to regular diet fed LinSTZ. On the other hand, HFD induced steatosis, liver fibrosis, inflammation, and increase in AST/ALT ratio, characteristics of non-alcoholic liver disease. Taken together, our results show that LinSTZ